title: [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
abstract: A pilot trial of combined chemotherapy with paclitaxel, doxorubicin and cisplatin was conducted in patients with advanced endometrial cancer. Between June 2000 and March 2002 8 patients were treated with combined chemotherapy, consisting of paclitaxel, 135 mg/m2; doxorubicin, 30 mg/m2; and cisplatin, 50 mg/m2 (TAP therapy). Patients received 3 to 5 courses of TAP therapy every 4 weeks. The major adverse effect was myelosuppression. All patients had grade 3 or 4 neutropenia, but did not have any severe infection with uncontrollable fever. Only 1 patient discontinued additional therapy due to grade 3 thrombocytopenia after 3 cycles. Grade 2 neurotoxicity occurred in 5 patients, but grade 3 was not observed. Among 5 patients with measurable tumors, 4 achieved partial response and 1 had no change of tumor size, indicating a response rate of 80.0%. We found that TAP therapy was feasible with G-CSF support and shows potential for high efficacy in advanced endometrial cancer.
authors.affiliation: Dept. of Obstetrics and Gynecology, School of Medicine, Sapporo Medical University.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Honma
authors.forename: Satoru
authors.initials: S
authors.lastname: Sagae
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Terasawa
authors.forename: Ryouichi
authors.initials: R
authors.lastname: Tanaka
authors.forename: Manabu
authors.initials: M
authors.lastname: Chida
authors.forename: Hisanobu
authors.initials: H
authors.lastname: Mizumoto
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ishioka
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Saito
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kudo
mesh_terms: D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin